PureTech Founded Entity Seaport Therapeutics Announces the Publication of New Research Demonstrating Increased Lymphatic Transport with up to 55 Percent Drug Absorption via Lymphatics with GlyphTM Platform
PureTech's Founded Entity, Seaport Therapeutics, published new research in Molecular Pharmaceutics showcasing enhanced drug transport capabilities of their Glyph platform. The study demonstrated up to 55% drug absorption via lymphatics, marking the highest reported level of lymphatic transport for the studied immunomodulatory drug.
The research evaluated modifications to mycophenolic acid (MPA), revealing that a new phenol attachment point achieved superior lymphatic transport and up to two-fold higher release in lymph nodes compared to previously reported attachment methods. The Glyph platform enables drugs to be absorbed through the intestinal lymphatic system like dietary fats, potentially benefiting therapeutic molecules with high first-pass metabolism issues.
PureTech ha fondato Seaport Therapeutics, che ha pubblicato nuove ricerche su Molecular Pharmaceutics mostrando capacità migliorate di trasporto dei farmaci della loro piattaforma Glyph. Lo studio ha dimostrato fino al 55% di assorbimento del farmaco tramite il sistema linfatico, segnando il livello più alto di trasporto linfatico riportato per il farmaco immunomodulatore studiato.
La ricerca ha valutato le modifiche all'acido micofenolico (MPA), rivelando che un nuovo punto di attacco del fenolo ha raggiunto un trasporto linfatico superiore e un rilascio fino a due volte superiore nei linfonodi rispetto ai metodi di attacco precedentemente riportati. La piattaforma Glyph consente ai farmaci di essere assorbiti attraverso il sistema linfatico intestinale come i grassi alimentari, potenzialmente beneficiando le molecole terapeutiche con elevati problemi di metabolismo di primo passaggio.
PureTech fundó Seaport Therapeutics, que publicó nueva investigación en Molecular Pharmaceutics mostrando capacidades mejoradas de transporte de fármacos de su plataforma Glyph. El estudio demostró hasta un 55% de absorción del fármaco a través de los linfáticos, marcando el nivel más alto de transporte linfático reportado para el fármaco inmunomodulador estudiado.
La investigación evaluó modificaciones al ácido micofenólico (MPA), revelando que un nuevo punto de unión de fenol logró un transporte linfático superior y hasta dos veces más liberación en los ganglios linfáticos en comparación con los métodos de unión reportados anteriormente. La plataforma Glyph permite que los fármacos sean absorbidos a través del sistema linfático intestinal como las grasas dietéticas, beneficiando potencialmente a las moléculas terapéuticas con altos problemas de metabolismo de primer paso.
PureTech는 Seaport Therapeutics를 설립하였으며, 이 회사는 Molecular Pharmaceutics에서 자사의 Glyph 플랫폼의 향상된 약물 운반 능력을 보여주는 새로운 연구 결과를 발표하였습니다. 이 연구는 연구된 면역 조절 약물에 대해 림프계를 통한 55% 약물 흡수를 입증하며, 이는 보고된 림프 운반 수준 중 가장 높은 수치입니다.
연구는 마이코페놀산(MPA)의 수정 사항을 평가하였으며, 새로운 페놀 결합점이 이전에 보고된 결합 방법에 비해 림프절에서의 림프 운반을 개선하고 두 배 더 높은 방출을 달성하였음을 밝혔습니다. Glyph 플랫폼은 약물이 식이 지방처럼 장 림프계에서 흡수될 수 있도록 하여, 첫 번째 통과 대사 문제로 어려움을 겪는 치료 분자에게 잠재적인 이점을 제공합니다.
PureTech a fondé Seaport Therapeutics, qui a publié de nouvelles recherches dans Molecular Pharmaceutics mettant en avant des capacités de transport de médicaments améliorées de leur plateforme Glyph. L'étude a démontré jusqu'à 55 % d'absorption du médicament via les lymphatiques, marquant le niveau le plus élevé de transport lymphatique signalé pour le médicament immunomodulateur étudié.
La recherche a évalué des modifications de l'acide mycophénolique (MPA), révélant qu'un nouveau point d'attache de phénol a permis d'obtenir un transport lymphatique supérieur et jusqu'à deux fois plus de libération dans les ganglions lymphatiques par rapport aux méthodes d'attache précédemment rapportées. La plateforme Glyph permet aux médicaments d'être absorbés par le système lymphatique intestinal comme les graisses alimentaires, ce qui pourrait bénéficier aux molécules thérapeutiques ayant de grands problèmes de métabolisme de premier passage.
PureTech hat Seaport Therapeutics gegründet, das neue Forschungsergebnisse in Molecular Pharmaceutics veröffentlicht hat, die verbesserte Arzneimitteltransportfähigkeiten ihrer Glyph-Plattform zeigen. Die Studie zeigte bis zu 55% Arzneimittelabsorption über die Lymphbahnen, was das höchste berichtete Niveau des lymphatischen Transports für das untersuchte immunmodulatorische Medikament darstellt.
Die Forschung bewertete Modifikationen der Mycophenolsäure (MPA) und zeigte, dass ein neuer Phenol-Anheftungspunkt einen überlegenen lymphatischen Transport und bis zu zweifach höhere Freisetzung in den Lymphknoten im Vergleich zu zuvor berichteten Anheftungsmethoden erreichte. Die Glyph-Plattform ermöglicht es, dass Medikamente über das intestinale lymphatische System wie Nahrungsfette aufgenommen werden, was potenziell therapeutischen Molekülen mit hohen First-Pass-Metabolismusproblemen zugutekommt.
- Achieved highest reported lymphatic transport level (55%) for the studied drug
- Demonstrated 2x higher drug release in lymph nodes compared to previous methods
- Platform shows potential for broad application in drugs with low bioavailability issues
- None.
Insights
The newly published research on Seaport Therapeutics' Glyph platform represents a significant technological breakthrough in drug delivery systems. The achievement of
This advancement has substantial commercial implications. The pharmaceutical industry faces persistent challenges with drug bioavailability and liver toxicity, which often derail otherwise promising drug candidates. The Glyph platform's ability to bypass first-pass metabolism could salvage many drug development programs that previously failed due to delivery challenges. This creates multiple revenue opportunities through:
- Internal drug development programs with improved efficacy profiles
- Potential licensing deals with pharmaceutical companies seeking to rescue failed drug candidates
- Applications in new drug development across various therapeutic areas
The platform's versatility, demonstrated through its success with mycophenolic acid, suggests broad applicability across different drug classes. This positions PureTech and Seaport Therapeutics favorably in the drug delivery technology market, estimated to be worth billions annually. The clinical validation of the platform significantly de-risks the technology and could accelerate partnership discussions with major pharmaceutical companies.
Looking ahead, this technology could particularly impact the development of neuropsychiatric medicines, where drug delivery across biological barriers has been a persistent challenge. The platform's ability to improve bioavailability while potentially reducing liver-related side effects could lead to safer, more effective treatments in this challenging therapeutic area.
Published data shows new site of Glyph prodrug attachment demonstrated highest reported level of lymphatic transport to date of the studied immunomodulatory drug
New linkers display up to two-fold higher release in lymph nodes compared to top-performing previously reported linkers
Research builds on prior evidence supporting the versatility of Glyph platform
The full text of the announcement from Seaport is as follows:
Seaport Therapeutics Announces the Publication of New Research Demonstrating Increased Lymphatic Transport with up to 55 Percent Drug Absorption via Lymphatics with GlyphTM Platform
Published data shows new site of Glyph prodrug attachment demonstrated highest reported level of lymphatic transport to date of the studied immunomodulatory drug
New linkers display up to two-fold higher release in lymph nodes compared to top-performing previously reported linkers
Research builds on prior evidence supporting the versatility of Glyph platform
The study evaluated ways of modifying mycophenolic acid (MPA), an immunomodulatory drug, to improve its absorption through the lymphatic system, and increase its concentration in lymph nodes, shown in preclinical models. Specifically, a comparison between distinct attachment points on the same drug molecule was made. A newly examined phenol attachment point showed the highest lymphatic transport of MPA reported to date – approximately 55 percent – and up to two-fold higher release in lymph nodes compared to the previously reported acid attachment point. The research demonstrated the impact of linker characteristics on the extent of lymphatic transport and release in the lymph nodes. Overall, these results help to underscore the benefits of a tailored lymphatic-targeting prodrug design approach.
“This research expands our understanding of lymphatic delivery and offers new insights for more effectively designing drugs with higher exposures at their intended targets, including immunomodulatory drugs used to treat a wide range of diseases,” said Christopher Porter, Ph.D., an original Co-inventor of the Glyph technology and Director of the Monash Institute of Pharmaceutical Sciences at Monash University in
With the Glyph platform, drugs are absorbed like dietary fats through the intestinal lymphatic system and transported into circulation. The Glyph platform has the potential to be widely applied to many therapeutic molecules that have high first-pass metabolism leading to low bioavailability and/or side effects, including liver enzyme elevations or hepatotoxicity. Seaport exclusively licensed this technology from Monash University based on the pioneering research of the Porter Research Group, including co-inventors Professor Porter and Jamie Simpson, Ph.D., who is now Head of Chemistry at Seaport Therapeutics.
“Our Glyph platform allows for a bespoke design approach, and this research reinforces the significance of the innovation behind our prodrug chemistry technology,” said Daniel Bonner, Ph.D., Co-founder, Senior Vice President, Platform, at Seaport Therapeutics. “Most importantly, Glyph has been clinically validated with demonstrated proof-of-concept data in humans and is being applied across Seaport’s pipeline of novel neuropsychiatric medicines, with enormous potential across a broad range of applications beyond CNS and neuropsychiatry.”
About the GlyphTM Platform
GlyphTM is Seaport’s proprietary technology platform which uses the lymphatic system to enable and enhance the oral administration of drugs. With the Glyph platform, drugs are absorbed like dietary fats through the intestinal lymphatic system and transported into circulation. The Glyph platform has the potential to be widely applied to many therapeutic molecules that have high first-pass metabolism leading to low bioavailability and/or side effects, including liver enzyme elevations or hepatotoxicity. Seaport exclusively licensed this technology from Monash University based on the pioneering research of the Porter Research Group. Advanced initially at PureTech Health and now at Seaport, Glyph has been applied to create therapeutic candidates for the Company’s pipeline resulting in new intellectual property, including composition of matter. The group and its collaborators have published research in Nature Metabolism, Frontiers in Pharmacology, Journal of Controlled Release and Molecular Pharmaceutics supporting the Glyph platform’s capabilities. See Glyph in action here.
About Seaport Therapeutics
Seaport Therapeutics is a clinical-stage biopharmaceutical company advancing the development of novel neuropsychiatric medicines in areas of high unmet patient needs. The Company has a proven strategy of advancing clinically validated mechanisms previously held back by limitations that are overcome with its proprietary GlyphTM technology platform. All the therapeutic candidates in its pipeline of first and best-in-class medicines are based on the Glyph platform, which is uniquely designed to enable oral bioavailability, bypass first-pass metabolism and reduce liver enzyme elevations or hepatotoxicity and other side effects. Seaport is led by an experienced team that invented and advanced important neuropsychiatric medicines and are guided by an extensive network of renowned scientists, clinicians and key opinion leaders. For more information, please visit www.seaporttx.com.
About PureTech Health
PureTech is a clinical-stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company has created a broad and deep pipeline through its experienced research and development team and its extensive network of scientists, clinicians and industry leaders that is being advanced both internally and through its Founded Entities. PureTech's R&D engine has resulted in the development of 29 therapeutics and therapeutic candidates, including three that have been approved by the
For more information, visit www.puretechhealth.com or connect with us on X (formerly Twitter) @puretechh.
Cautionary Note Regarding Forward-Looking Statements
This press release contains statements that are or may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation those related to Seaport’s development plans for its pipeline of neuropsychiatric therapeutics based on the Glyph Platform, the applicability of the platform beyond neuropsychiatry, potential benefits to patients, and Seaport’s and our future prospects, developments and strategies. The forward-looking statements are based on current expectations and are subject to known and unknown risks, uncertainties and other important factors that could cause actual results, performance and achievements to differ materially from current expectations, including, but not limited to, those risks, uncertainties and other important factors described under the caption "Risk Factors" in our Annual Report on Form 20-F for the year ended December 31, 2023, filed with the SEC and in our other regulatory filings. These forward-looking statements are based on assumptions regarding the present and future business strategies of the Company and the environment in which it will operate in the future. Each forward-looking statement speaks only as at the date of this press release. Except as required by law and regulatory requirements, we disclaim any obligation to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250212925895/en/
PureTech
Public Relations
publicrelations@puretechhealth.com
Investor Relations
IR@puretechhealth.com
Ben Atwell, Rob Winder
+44 (0) 20 3727 1000
puretech@fticonsulting.com
US Media
Justin Chen
+1 609 578 7230
justin@tenbridgecommunications.com
Source: PureTech Health plc
FAQ
What is the significance of the 55% lymphatic transport achievement in PRTC's Glyph platform?
How does the new phenol attachment point improve drug delivery in PRTC's Glyph platform?
What therapeutic applications could benefit from PRTC's Glyph platform technology?
How does PRTC's Glyph platform transport drugs through the body?
